These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 24308832)

  • 1. Anakinra for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2014 Jan; 10(1):7-18. PubMed ID: 24308832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
    Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
    Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges.
    Kuemmerle-Deschner JB; Verma D; Endres T; Broderick L; de Jesus AA; Hofer F; Blank N; Krause K; Rietschel C; Horneff G; Aksentijevich I; Lohse P; Goldbach-Mansky R; Hoffman HM; Benseler SM
    Arthritis Rheumatol; 2017 Nov; 69(11):2233-2240. PubMed ID: 28692792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryopyrin-associated periodic syndromes: diagnosis and management.
    Miyamae T
    Paediatr Drugs; 2012 Apr; 14(2):109-17. PubMed ID: 22335455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal urticaria: Could it be CAPS?
    Cutts L; Parslew R; Eustace K
    Pediatr Dermatol; 2018 Nov; 35(6):e420-e421. PubMed ID: 30187963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1β and rapid response to anakinra.
    Sabroe RA; Stokes CA; Parker LC; Higgins K; Prince LR; Sabroe I
    Clin Exp Dermatol; 2013 Dec; 38(8):874-7. PubMed ID: 23889084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes: what did we learn?
    Koné-Paut I; Piram M
    Autoimmun Rev; 2012 Nov; 12(1):77-80. PubMed ID: 22884551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome.
    Mitroulis I; Skendros P; Ritis K
    Eur J Intern Med; 2010 Jun; 21(3):157-63. PubMed ID: 20493414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors.
    Bertoni A; Carta S; Baldovini C; Penco F; Balza E; Borghini S; Di Duca M; Ognio E; Signori A; Nozza P; Schena F; Castellani P; Pastorino C; Perrone C; Obici L; Martini A; Ceccherini I; Gattorno M; Rubartelli A; Chiesa S
    J Allergy Clin Immunol; 2020 Jan; 145(1):368-378.e13. PubMed ID: 31194989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muckle-Wells treatment with anakinra.
    Eungdamrong J; Boyd KP; Meehan SA; Latkowski JA
    Dermatol Online J; 2013 Dec; 19(12):20720. PubMed ID: 24365011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty year follow up of a patient with a new de-novo NLRP3 mutation (S595G) and CINCA syndrome.
    Kanariou M; Dracou C; Spanou K; Möller J; Rösen-Wolff A; Schuster V; Roesler J
    Klin Padiatr; 2009; 221(6):379-81. PubMed ID: 19890791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA.
    Goldbach-Mansky R
    Curr Rheumatol Rep; 2011 Apr; 13(2):123-31. PubMed ID: 21538043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
    Walsh GM
    Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryopyrin-associated periodic syndromes: background and therapeutics.
    Kubota T; Koike R
    Mod Rheumatol; 2010 Jun; 20(3):213-21. PubMed ID: 20140476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two adult siblings with atypical cryopyrin-associated periodic syndrome due to a novel M299V mutation in NLRP3.
    Verma D; Eriksson P; Sahdo B; Persson A; Ejdebäck M; Särndahl E; Söderkvist P
    Arthritis Rheum; 2010 Jul; 62(7):2138-43. PubMed ID: 20506209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS).
    Haverkamp MH; van de Vosse E; Goldbach-Mansky R; Holland SM
    Clin Exp Immunol; 2014 Sep; 177(3):720-31. PubMed ID: 24773462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
    Church LD; McDermott MF
    Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryopyrin-associated periodic syndrome.
    Giat E; Lidar M
    Isr Med Assoc J; 2014 Oct; 16(10):659-61. PubMed ID: 25438464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.